Navigation Links
Reportlinker Adds Product Profiles: Depression - Next generation Vies for Second-Line Patients
Date:6/27/2011

NEW YORK, June 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Product Profiles: Depression - Next generation vies for second-line patients

http://www.reportlinker.com/p0564398/Product-Profiles-Depression---Next-generation-vies-for-second-line-patients.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Introduction

Patents for the current market-leading depression brands are due to expire in the major markets between 2012 and 2015, by which time competition in the market will be at its fiercest. In order to flourish in this harsh environment, new antidepressants must be sufficiently differentiated from conventional monoamine neurotransmitter reuptake inhibitors.

Features and benefits

* Understand Datamonitor's independent appraisal of marketed brands and key pipeline agents indicated for treating depression.

* Illustrate how pipeline and marketed drugs compare to one another in terms of clinical and commercial attributes.

* Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.

* Understand how marketed brands are positioned in the depression treatment algorithm and how they are perceived by psychiatrists.

* Determine to what extent future therapies satisfy the main clinical unmet needs in depression treatment.

Highlights

Datamonitor's physician survey reveals that psychiatrists perceive Forest's and Lundbeck's selective serotonin reuptake inhibitor Lexapro (escitalopram) to be the leading depression treatment, with a superior efficacy and tolerability profile to other antidepressant brands.

Valdoxan (agomelatine; Servier/Novartis) and several pipeline antidepressants are poised to usurp Lexapro, following its loss of market exclusivity, and become the most attractive depression brands.

Forest's Viibryd (vilazodone) has the hallmarks of a new blockbuster – a novel mode of action, favorable tolerability, and the marketing prowess of Forest. Viibryd will be well received due to its good tolerability, although commercial success comparable to Lexapro will be unattainable as more innovative competitor drugs near the US market.

Your key questions answered

* What is the gold-standard drug for depression?

* How are marketed brands positioned in the depression treatment algorithm?

* Which are the most likely drugs to emerge from the pipeline and how will they impact the way depression is treated?

* What are the comparative strengths and weaknesses of the key depression brands and pipeline candidates?

Executive Summary

Strategic scoping and focus

Datamonitor key findings

Related reports

OVERVIEW

Catalyst

Summary

MARKET DEFINITION AND OVERVIEW

Product overview

MARKETED PRODUCT PROFILES

Lexapro (escitalopram; Forest/Lundbeck)

Drug profile

Development overview

SWOT analysis

Product positioning

Physicians' perceptions of Lexapro

Clinical and commercial attractiveness

Effexor XR (venlafaxine extended release; Pfizer)

Drug profile

Development overview

SWOT analysis

Product positioning

Clinical and commercial attractiveness

Pristiq (desvenlafaxine; Pfizer)

Drug profile

Development overview

SWOT analysis

Product positioning

Physicians' perceptions of Pristiq

Clinical and commercial attractiveness

Cymbalta (duloxetine; Eli Lilly/Shionogi)

Drug profile

Development overview

SWOT analysis

Product positioning

Physicians' perceptions of Cymbalta

Clinical and commercial attractiveness

Valdoxan (agomelatine; Servier/Novartis)

Drug profile

Development overview

SWOT analysis

Product positioning

Physicians' perceptions of Valdoxan

Clinical and commercial attractiveness

Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka)

Drug profile

Development overview

SWOT analysis

Product positioning

Physicians' perceptions of Abilify

Clinical and commercial attractiveness

Seroquel XR (quetiapine extended release; AstraZeneca)

Drug profile

Development overview

SWOT analysis

Product positioning

Physicians' perceptions of Seroquel XR

Clinical and commercial attractiveness

Oleptro (trazodone extended release; Labopharm)

Drug profile

Development overview

SWOT analysis

Product positioning

Clinical and commercial attractiveness

Other marketed drugs for depression

Remeron (mirtazapine; Merck & Co./Meiji Seika)

PIPELINE PRODUCT PROFILES

Viibryd (vilazodone; Forest)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

Lu AA21004 (Lundbeck/Takeda)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

TC-5214 (Targacept/AstraZeneca)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

Levomilnacipran (F2695; Forest/Pierre Fabre)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

Edivoxetine (LY2216684; Eli Lilly)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

Vyvanse (lisdexamfetamine; Shire)

Drug profile

Development overview

SWOT analysis

Satisfaction of unmet needs

Clinical and commercial attractiveness

Other drugs in development for depression

CPI-300 (bupropion; IntelGenx)

AZD6765 (AstraZeneca)

BCI-224 (sabcomeline; BrainCells)

BCI-540 (coluracetam; BrainCells/Mitsubishi Tanabe)

BCI-952 (melatonin and buspirone; Brain Cells)

BMS-820836 (Bristol-Myers Squibb/AMRI)

Cariprazine (RGH-118; Forest/Gedeon Richter/Mitsubishi Tanabe)

Cimicoxib (UR-8880; Affectis Pharmaceuticals/Palau Pharma)

CP-601,927 (Pfizer)

EB-1010 (Euthymics Bioscience)

GLYX-13 (Naurex)

JNJ-26489112 (Johnson & Johnson)

Lu AA24530 (Lundbeck/Takeda)

OPC-34712 (Otsuka)

Orvepitant (GSK823296; GlaxoSmithKline)

PNB-01 (pipamperone and citalopram; PharmaNeuroBoost)

RG7090 (Roche)

SA4503 (cutamesine; M's Science)

Serdaxin (clavulanic acid; Rexahn Pharmaceuticals)

SSR125543 (Sanofi)

Tasimelteon (VEC-162; Vanda Pharmaceuticals)

TriRima (CX157; CeNeRx/Krenitsky Pharmaceuticals)

BIBLIOGRAPHY

Journal papers

Websites

Datamonitor reports

APPENDIX A – SURVEY INFORMATION

Physician research methodology

Physician sample breakdown

The survey questionnaire

Introduction

Section one: diagnosis and patient segmentation

Section two: treatment of major depressive disorder

Section three: product profiles

Demographics

APPENDIX B

PharmaVitae Explorer database

Contributing experts

Conferences attended

Report methodology

To order this report:

Drug and Medication Industry: Product Profiles: Depression - Next generation vies for second-line patients

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017  Additive Orthopaedics, LLC., an early ... has kicked off a multi-centered clinical study to ... segments. According to Brian McLaughlin ... lattice structures have already shown tremendous post-operative success ... allograft wedges from which we have seen evidence ...
(Date:3/23/2017)... --  The goal of the pilot is to build ... drugs as they are distributed in the ... US FDA to better protect consumers by improving counterfeit ... Blockchain startup Chronicled, which links the physical and ... and recently raised $6.25M, and the LinkLab, a life ...
(Date:3/23/2017)... 23, 2017 The global ... with the top five players accounting for nearly ... companies are Stryker Sustainability Solutions, Ethicon (Johnson & ... and VANGUARD AG. Despite the high level of ... witnessing the prevalence of fierce competition among the ...
Breaking Medicine Technology:
(Date:3/23/2017)... , ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and ... and Director, AMN Healthcare: Susan Salka , 43rd President of the United States ... Big Fight My Life In and Out of the Ring: Sugar Ray Leonard , ...
(Date:3/23/2017)... ... March 23, 2017 , ... According to the National Sleep Foundation , ... not the only cause of the sunken-eye look, which can include dark circles or ... in poor health are likely due to genetics, dehydration, allergies, and losing fat beneath ...
(Date:3/23/2017)... Raleigh, NC (PRWEB) , ... March 23, 2017 , ... ... the ride). Life is serious so build on a solid foundation. As experts ... high priority vital information that is coming soon. Inflownomics deliver ripe, fresh, clean & ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... with all Americans facing life-altering and fatal diseases in opposition to the ... decisions that would eviscerate care, services, and hope for the most vulnerable among ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... European Guidelines and the New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews ... http://www.fdanews.com/mdclineval                  , How will the new EU MDR language change the ...
Breaking Medicine News(10 mins):